Search

Your search keyword '"Lehodey B"' showing total 6 results
Start Over Author "Lehodey B"
6 results on '"Lehodey B"'

2. Dynamics of the X-ray clusters Abell 222, Abell 223 and Abell 520

Author

Proust, D., Cuevas, H., Capelato, H. V., Sodre Jr., L., Lehodey, B. Tome, Fevre, O. Le, and Mazure, A.

Subjects
Astrophysics
Abstract

We present the results of a dynamical analysis of three rich, X-ray luminous galaxy clusters, Abell 222, Abell 223 and Abell 520, that are at intermediate redshifts. Our study is based on radial velocities for 71 cluster members, respectively 30 for A222, 20 for A223 and 21 for A520, measured from spectra obtained at the Canada-France-Hawaii Telescope, the European Southern Observatory, and the Pic du Midi Observatory, and supplemented with radial velocities from the literature. A222 galaxies have slightly higher velocities than those of A223, with bi-weighted mean velocity of V_{bi} = 64242 +/- 194 km/s for A222, and of V_{bi} = 63197 +/- 266 km/s for A223. The velocity dispersions of the two clusters are about the same: sigma_{bi} = 1013 +/- 150 km/s and sigma_{bi} = 1058 +/- 160 km/s for A222 and A223, respectively. For A520 we obtain V_{bi} = 60127 +/- 284 km/s with sigma_{bi} = 1250 +/- 189 km/s. We also give mass and mass-luminosities ratio estimates for each cluster separately. We argue that these clusters are presently undergoing strong dynamical evolution and that A222 and A223 will probably merge in the future. We have applied a Principal Component Analysis to a sample of 51 CFHT spectra to produce a spectral classification for these galaxies. This classification has allowed us to show that the morphological and kinematical segregations were already established in these intermediate redshift clusters., Comment: Accepted for publication in A&A. 12 pages, 15 eps figures

Published
2000

4. Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial

Author

Pierre-Marie Roy, Raphaëlle Lopez, Mustapha Sebbane, Charlotte Steinier, Benjamin Planquette, Nicolas Falvo, Tali-Anne Szwebel, Olivier Hugli, Ygal Benhamou, Jeannot Schmidt, Nicolas Dublanchet, Magali Bartiaux, Alexandre Ghuysen, Delphine Douillet, Antoine Elias, Luc-Marie Joly, Isabelle Mahé, Nicolas Javaud, Laura M. Faber, Francis Couturaud, Isabelle Quéré, Jerome Bokobza, Karine Montaclair, Menno V. Huisman, Damien Viglino, Rosen Cren, Armelle Arnoux, Andrea Penaloza, Gilles Chatellier, Frits I. Mulder, Henry Juchet, Stephan V. Hendriks, Frederikus A. Klok, François-Xavier Lapébie, Thomas Moumneh, Marie Daoud-Elias, Guy Meyer, Gilles Pernod, David Jiménez, Olivier Sanchez, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), F-Crin Innovte [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Université Catholique de Louvain = Catholic University of Louvain (UCL), Cliniques Universitaires Saint-Luc [Bruxelles], Lausanne University Hospital, Leiden University Medical Center (LUMC), Universiteit Leiden, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Services des urgences [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), University Hospital Sart Tilman [Liège, Belgium], Rode Kruis Hospital Beverwijk, Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hypoxie et PhysioPathologie (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), CHU Grenoble, Pôle Urgences [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Université Clermont Auvergne (UCA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Louis Mourier - AP-HP [Colombes], Hôpital Saint-Pierre, Bruxelles, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Le Mans (CH Le Mans), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-ThEMAS ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), CHU Clermont-Ferrand, Hôpital Lapeyronie [Montpellier] (CHU), Université de Montpellier (UM), Universidad de Alcalá de Henares (UAH), Graduate School, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, HOME-PE Study Group, Feral, A.L., Pastré, J., Roche, A., Cornand, D., Martinez, P., Poggi, J.N., Rezkallah, S., Belizna, C., Bigou, Y., Carraro, Q., Friou, E., Gourdier, A.S., Palous, C., Goetghebeur, D., Armengol, G., Tzebia, C., Dumas, F., Maignan, M., Moustafa, F., Charpentier, S., Bura-Rivière, A., Maillet, F., Plaisance, L., Galanaud, J.P., Henneton, P., Jreige, R., Lehodey, B., Honnart, D., Tfifha, R., Schotte, T., Al Dandachi, G., Simoneau, G., Le Coat, A., Casarin, C., Cismas, A., Germeau, B., Grégoire, C., Hainaut, P., Hermans, C., Lambert, C., Steenebrugge, F., Muriel, M., Moonen, S., Gabrovska, M., Kreps, B., de Longueville, D., Mols, P., Delvaux, P., Van Nuffelen, M., Motte, S., Kamphuisen, P.W., Bresser, C., Hendriks, S., Mairuhu, ATA, van der Pol, L., Fogteloo, A.J., Nijkeuter, M., de Winter, M., Chatellier, G., Hugli, O., Huisman, M., Jimenez, D., Klok, F.A., Meyer, G., Penaloza, A., Roy, P.M., Sanchez, O., Girard, P., den Exter, P., Parent, F., Aujesky, D., Bounameaux, H., Laporte, S., Ten Cate, H., Gable, B., Augereau, C., Chrétien, J.M., Goraguer, A., Houssin, E., Leconte, L., Smii, S., Lasri, F., Haton, C., Marquette, A., Mercier, M., Abello, M., Mitri, F., Leclerq, C., Giansily, D., Aubert, C., Ragueneau, C., Baty, N., Veillon, A.S., Le Gall, B., Bulte, C., Pontdemé, G., Chibah, A., Atia, Y., Makele, P.M., Bouchafa, F., Camminada, C., Hebrard, M., Pelvet, B., Baudoin, D., Pinson, M., Helfer, H., Lefebvre, S., Pontal, D., Lextreyt, B., Bernard, C., Robert, A., Pichon, I., Beuvard, E., Dekeister, A.C., Leon, C., Gerhard-Donnet, H., Moll, S., and de Bruijn, M.

Subjects
medicine.medical_specialty, Randomization, Cardiologie et circulation, Population, Severity of Illness Index, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, Randomized controlled trial, Clinical Research, law, medicine, Humans, AcademicSubjects/MED00200, education, Risk assessment, education.field_of_study, Intention-to-treat analysis, business.industry, Emergency department, Acute Disease, Patient Discharge, Prognosis, Pulmonary Embolism/drug therapy, Risk Assessment, Clinical decision-making, Home treatment, Pulmonary embolism, Absolute risk reduction, medicine.disease, Hospitals, Thrombosis and Antithrombotic Treatment, Hospitalization, Embolism, Emergency medicine, Cardiology and Cardiovascular Medicine, business
Abstract

AIMS: The aim of this study is to compare the Hestia rule vs. the simplified Pulmonary Embolism Severity Index (sPESI) for triaging patients with acute pulmonary embolism (PE) for home treatment. METHODS AND RESULTS: Normotensive patients with PE of 26 hospitals from France, Belgium, the Netherlands, and Switzerland were randomized to either triaging with Hestia or sPESI. They were designated for home treatment if the triaging tool was negative and if the physician-in-charge, taking into account the patient's opinion, did not consider that hospitalization was required. The main outcomes were the 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death (non-inferiority analysis with 2.5% absolute risk difference as margin), and the rate of patients discharged home within 24 h after randomization (NCT02811237). From January 2017 through July 2019, 1975 patients were included. In the per-protocol population, the primary outcome occurred in 3.82% (34/891) in the Hestia arm and 3.57% (32/896) in the sPESI arm (P = 0.004 for non-inferiority). In the intention-to-treat population, 38.4% of the Hestia patients (378/984) were treated at home vs. 36.6% (361/986) of the sPESI patients (P = 0.41 for superiority), with a 30-day composite outcome rate of 1.33% (5/375) and 1.11% (4/359), respectively. No recurrent or fatal PE occurred in either home treatment arm. CONCLUSIONS: For triaging PE patients, the strategy based on the Hestia rule and the strategy based on sPESI had similar safety and effectiveness. With either tool complemented by the overruling of the physician-in-charge, more than a third of patients were treated at home with a low incidence of complications., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021
Full Text
View/download PDF

5. MEESSI-AHF score to estimate short-term prognosis of acute heart failure patients in the Emergency Department: a prospective and multicenter study.

Author

Oberlin M, Buis G, Alamé K, Martinez M, Bitard MP, Berard L, Losset X, Balen F, Lehodey B, Taheri O, Delannoy Q, Kepka S, Tran DM, Bilbault P, Godet J, and Le Borgne P

Subjects
Adult, Humans, Prospective Studies, Acute Disease, Prognosis, Emergency Service, Hospital, Heart Failure diagnosis, Heart Failure therapy
Abstract

Background: The assessment of acute heart failure (AHF) prognosis is primordial in emergency setting. Although AHF management is exhaustively codified using mortality predictors, there is currently no recommended scoring system for assessing prognosis. The European Society of Cardiology (ESC) recommends a comprehensive assessment of global AHF prognosis, considering in-hospital mortality, early rehospitalization rates and the length of hospital stay., Objective: We aimed to prospectively evaluate the performance of the Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF (MEESSI-AHF) score in estimating short prognosis according to the ESC guidelines., Design, Settings and Patients: A multicenter study was conducted between November 2020, and June 2021. Adult patients who presented to eleven French hospitals for AHF were prospectively included., Outcome Measures and Analysis: According to MEESSI-AHF score, patients were stratified in four categories corresponding to mortality risk: low-, intermediate-, high- and very high-risk groups. The primary outcome was the number of days alive and out of the hospital during the 30-day period following admission to the Emergency Department (ED)., Results: In total, 390 patients were included. The number of days alive and out of the hospital decreased significatively with increasing MEESSI-AHF risk groups, ranging from 21.2 days (20.3-22.3 days) for the low-risk, 20 days (19.3-20.5 days) for intermediate risk,18.6 days (17.6-19.6 days) for the high-risk and 17.9 days (16.9-18.9 days) very high-risk category., Conclusion: Among patients admitted to ED for an episode of AHF, the MEESSI-AHF score estimates with good performance the number of days alive and out of the hospital., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

6. Impact of laryngeal tube use on chest compression fraction during out-of-hospital cardiac arrest. A prospective alternate month study.

Author

Maignan M, Koch FX, Kraemer M, Lehodey B, Viglino D, Monnet MF, Pham D, Roux C, Genty C, Rolland C, Bosson JL, Danel V, and Debaty G

Subjects
Accelerometry methods, Aged, Cardiopulmonary Resuscitation adverse effects, Cardiopulmonary Resuscitation methods, Defibrillators adverse effects, Equipment Failure Analysis, Equipment Safety, Female, France, Humans, Male, Outcome and Process Assessment, Health Care, Fractures, Bone etiology, Fractures, Bone prevention & control, Intubation, Intratracheal instrumentation, Out-of-Hospital Cardiac Arrest therapy
Abstract

Aim: Supraglottic devices are thought to allow efficient ventilation and continuous chest compressions during cardiac arrest. Therefore, the use of supraglottic devices could increase the chest compression fraction (CCF), a critical determinant of patient survival. The aim of this study was to assess the CCF in out-of-hospital cardiac arrest (OHCA) patients ventilated with a supraglottic device., Methods: We conducted an open prospective multicenter study with temporal clusters. OHCA patients treated by emergency nurses received either intermittent chest compressions with bag-valve mask ventilations (30:2 rhythm; BVM group); or continuous chest compressions with asynchronous ventilations by laryngeal tube (LT group). The primary endpoint was the CCF assessed using an accelerometer connected to the defibrillator. We also investigated the ease of use of the laryngeal tube., Results: Eighty-two patients were included (41 in each group); 68% were male and the median age was 68 (54-80) years. Patients and cardiac arrest characteristics did not differ between groups. The CCF was 75% (68-79%) in the LT group and 59% (51-68%) in the BVM group (p<0.01). LT insertion failed in nine out of 40 cases (23%). The median time of LT insertion was 26s (11-56 s). CCF was significantly lower when LT insertion failed (58% (48-74%) vs. 76% (72-80%) when LT insertion succeeded; p=0.01)., Conclusion: The use of the LT during OHCA increases the CCF when compared to standard BVM ventilation. However, the impact of LT use on mortality remains unclear., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results